Differentiated thyroid cancer and selenium supplements for protection of salivary glands from 131I treatment

被引：0
|
作者：
Mazokopakis, Elias E. [1 ]
机构：
[1] Naval Hosp Crete, Dept Internal Med, Khania 73200, Crete, Greece
来源：
HELLENIC JOURNAL OF NUCLEAR MEDICINE | 2018年 / 21卷 / 01期
关键词：
HASHIMOTOS-THYROIDITIS; MANAGEMENT;
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：83 / 84
页数：2
相关论文
共 50 条
  • [1] 131I imaging in the therapy of differentiated thyroid cancer
    Vija, L. -M.
    Toubert, M. -E.
    MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE, 2012, 36 (01): : 44 - 51
  • [2] Effects of recombinant human thyroid stimulating hormone on 131I therapy for the treatment of differentiated thyroid cancer
    Guo, Yiling
    Zhang, Yingnan
    Chen, Zuowei
    Xin, Zhenfu
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2015, 9 (05) : 1847 - 1850
  • [3] Clinical pathway of metabolic therapy with 131I in differentiated thyroid cancer
    Saiz, I. Blanco
    Apinaniz, E. Anda
    Arribas, J. Pineda
    Moreno, F. Caudepon
    Iglesias, A. Fernandez
    Jimenez, M. Huarte
    Munoz, A. I. de Miguel
    Aristorena, M. I. Irigoyen
    Girones, E. Goni
    REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR, 2023, 42 (03): : 178 - 187
  • [4] Impact of thyroiditis on 131I uptake during ablative therapy for differentiated thyroid cancer
    Lim, Eugenie S.
    Shah, Shanty G.
    Waterhouse, Mona
    Akker, Scott
    Drake, William
    Plowman, Nick
    Berney, Daniel M.
    Richards, Polly
    Adams, Ashok
    Nowosinska, Ewa
    Brennan, Carmel
    Druce, Maralyn
    ENDOCRINE CONNECTIONS, 2019, 8 (05): : 571 - 578
  • [5] Predictors of success of the ablative/therapeutic radioiodine (131I) in differentiated thyroid cancer
    Fard-Esfahani, Armaghan
    Valipouri, Mohammad Reza
    Harsini, Sara
    Beiki, Davood
    Emami-Ardekani, Alireza
    Fallahi, Babak
    Eftekhari, Mohammad
    IRANIAN JOURNAL OF NUCLEAR MEDICINE, 2020, 28 (01): : 14 - 20
  • [6] Advantages of dosimetry in 131I therapy of differentiated thyroid carcinoma
    Verburg, Frederik A.
    QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 63 (03): : 253 - 257
  • [7] Radiation dose rates of differentiated thyroid cancer patients after 131I therapy
    Jin, Pingyan
    Feng, Huijuan
    Ouyang, Wei
    Wu, Juqing
    Chen, Pan
    Wang, Jing
    Sun, Yungang
    Xian, Jialang
    Huang, Liuhua
    RADIATION AND ENVIRONMENTAL BIOPHYSICS, 2018, 57 (02) : 169 - 177
  • [8] 131I SPECT/CT provides prognostic information in patients with differentiated thyroid cancer
    Heinrich, Marieke
    Blickle, Elias
    Hartrampf, Philipp E.
    Hasenauer, Natalie
    Kosmala, Aleksander
    Kerscher, Alexander
    Schlegel, Nicolas
    Verburg, Frederik A.
    Buck, Andreas K.
    Michalski, Kerstin
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2025,
  • [9] Value of 131I SPECT/CT for the evaluation of differentiated thyroid cancer: a systematic review of the literature
    Xue, Yan-Li
    Qiu, Zhong-Ling
    Song, Hong-Jun
    Luo, Quan-Yong
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 (05) : 768 - 778
  • [10] Analysis of the incidence and influencing factors of hyponatremia before 131I treatment of differentiated thyroid carcinoma
    Cao, Jing-Jia
    Yun, Can-Hua
    Xiao, Juan
    Liu, Yong
    Wei, Wei
    Zhang, Wei
    WORLD JOURNAL OF CLINICAL CASES, 2021, 9 (36) : 11173 - 11182
12345